{"id":"W3094693153","doi":"10.1136/annrheumdis-2020-eular.3908","title":"OP0230 EFFICACY AND SAFETY OF TILDRAKIZUMAB, A HIGH-AFFINITY ANTI–INTERLEUKIN-23P19 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS IN A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE, PHASE 2B STUDY","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Celgene; GlaxoSmithKline; Pfizer","keywords":"Medicine; Placebo; Psoriasis Area and Severity Index; Psoriatic arthritis; Internal medicine; Tolerability; Adverse effect; Psoriasis; Arthritis; Immunology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001937434,0.00159808,0.002968478,0.0004151367,0.0003586935,0.0009958151,0.0006968039,0.001642562,0.003472754],"category_scores_gemma":[0.001110633,0.000733164,0.001625193,0.0003207933,0.0009982963,0.0009885051,0.000312345,0.002452851,0.00105997],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005070386,"about_ca_system_score_gemma":0.0007806114,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000670556,"about_ca_topic_score_gemma":0.0011711,"domain_scores_codex":[0.9993674,0.0003078685,0.00003744541,0.00009488114,0.00006775173,0.0001246915],"domain_scores_gemma":[0.9992894,0.0001831633,0.000116762,0.0000527297,0.00005289676,0.000305061],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9468439,0.01022459,0.0008708732,0.0006003145,0.0008497317,0.00008206825,0.00006817935,0.0004414292,0.01661099,0.00009386129,0.0007671505,0.02254695],"study_design_scores_gemma":[0.8742337,0.1187877,0.004548428,0.00001920498,0.0004260443,0.0000754901,0.00001824594,0.0003660829,0.0008491463,0.0001001356,0.0005564895,0.00001935755],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924688,0.003471533,0.0004464161,0.0003701203,0.000228321,0.000993254,0.0006289051,0.00009061711,0.001302019],"genre_scores_gemma":[0.9921108,0.001936409,0.0006482797,0.0007317378,0.0002974154,0.001023903,0.0009949668,0.00002465092,0.002231864],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003472754,"threshold_uncertainty_score":0.01161748,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02872775325592086,"score_gpt":0.288950073903833,"score_spread":0.2602223206479122,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}